Mangalam drug update

PHARMA SECTOR RETURN ON EQUITY
ONE OF THE RATIO IMPORTANT FOR COMPANY EVALUATION.
🌋🌋🌋🌋🌋🌋🌋🌋🌋🌋🌋🌋🌋
THESE LIST INCLUDE SOME OF MAJOR PHARMA COMPANY.

SUN PHARMA :22.50%

CIPLA :8.73%

PIRAMAL ENTERPRISE :7.78%

CADILA HEALTHCARE :27%

AUROBINDO PHARMA :23%

DR REDDY LAB:10.5%

LUPIN LTD:21%

BIOCON :15%

ALEMBIC LAB:22%

TORRENT PHARMA :23%

GLAXOSMITHKLINE :16%

GLENMARK :27%

NATCO PHARMA:33%

AJANTA PHARMA :37%

ABOTT INDIA :21%

SANOFI:17%

ALEMBIC PHARMA :23%

DISHMAN PHARMA :12%

PFIZER :15%

WORKHORD :(-6%)

STRIDE SHASHUN:16%

IPCA LAB:8%

FDC LTD:16%

GRANULES :18%
🌋🌋🌋🌋🌋🌋🌋🌋🌋🌋🌋🌋🌋
AVG RETURN ON EQUITY COMES AROUND 18% FOR PHARMA SECTOR.
🌋🌋🌋🌋🌋🌋🌋🌋🌋🌋🌋🌋
MANGALAM DRUG RETURN ON EQUITY
27.50% MORE THAN AVG PHARMA SECTOR AND MANY BIG PHARMA COMPANIES.
WHICH EXPECTED TO BE 35% IN 2018.

MANGALAM DRUG A VALUE BUY

Author: Atul Singh Stock Market Analyst

Disclaimer: This Blog, its owner, creator / contributor is not a research analyst and expressing opinion only as an individual investor in Indian equities. He/She is not responsible for any loss arising out of any information, post or opinion appearing on this blog. Investors are advised to consult financial consultant before acting on any such information. All information in this blog is posted for personal study, All information posted on blog is as available in public domain.

Leave a Reply

Your email address will not be published. Required fields are marked *